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Introduction: Pulmonary dynamic hyperinflation (DH) is an important factor limiting the
physical capacity of patients with COPD. Inhaled bronchodilator should be able to reduce DH.
Objective: To measure DH in COPD patients during upper limbs exercise tests with previous use
of bronchodilator or placebo, and to evaluate the respiratory pattern to justify the dynamics of
hyperinflation.
Methods: Inspiratory capacity (IC) of 16 patients with COPD (age: 63  13 years; FEV1 of
1.5 0.7 Le41 11% predicted) was measured before and after an incremental arm exercise
test (diagonal technique) with randomly and double-blinded inhaled placebo or salbutamol.
Results: Rest IC increased from 2.32 0.44 L to 2.54 0.39 L after inhalation of 400 mcg of
salbutamol (pZ 0.0012). There was a decrease in the IC after a maximal incremental arm
exercise test, 222 158 ml (pZ 0.001) with placebo use, but no change was seen after the
salbutamol use: 104 205 ml (pZ 0.41); 62% of the patients presented a 10% or more reduc-
tion in the IC after the exercise with placebo. There was a correlation between DH and lower
FEV1/FVC (pZ 0.0067), FEV1 predicted (pZ 0.0091) and IC% predicted (pZ 0.043) and higher
VO2 ml/Kg/min % predicted (pZ 0.05). Minute ventilation and respiratory rate were higher
during the exercise with placebo (pZ 0.002) whereas VE/MVV ratio was lower in the exercise
after salbutamol (p> 0.05).Diseases (Pneumologia e Unifesp), Rua Botucatu, 740, 3 Andar, 04023-062 Sa˜o Paulo SP, Brazil.
o.com.br (J.R. Jardim).
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252 E.F. Porto et al.Conclusion: We conclude that the use of bronchodilator increases the IC of patient with COPD
and may help not to increase the DH during a maximal exercise with the arms.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
preventable and treatable respiratory impairment charac-
terized by non-reversible airflow obstruction. Airflow
obstruction is progressive and it is associated with an
abnormal inflammatory response in the lungs due to toxic
gases and particles, especially caused by tobacco use.
Although COPD affects the lungs, it has also systemic
consequences.1
COPD patients, especially those with moderate and
severe airway obstruction, have a longer expiratory flow
leading to lung airway trapping and hyperinflation,
especially during effort. Expiratory impairment is basically
caused by loss of pulmonary elastic recoil, bronquiolar axial
traction reduction and bronquial inflammation.2
Dynamic pulmonary hyperinflation imposes an additional
workload on the respiratory muscles, being determinant for
the inspiratory muscles mechanical disadvantage. It is
conceivable that dynamic hyperinflation could develop
during efforts accomplished by upper limbs. It is known that
minimal muscle mass may generate a high amount of
lactate with enhancement of the respiratory drive resulting
in increasing respiratory rate and shorter expiratory time.
Short expiratory time is associated to hyperinflation.3,4
Upper limb’s ability is responsible for the accomplishment
of 80% of daily living activities (ADL).5,6 However, there is not
much information on the physiological response to upper limb
exercises.We hypothesize that upper limbs physical activities
lead to dynamic pulmonary hyperinflation which may be
prevented and reduced with bronchodilator use.
So, the objectives of this study were to measure
dynamic pulmonary hyperinflation in patients with COPD
during upper limb exercise tests with previous bronchodi-
lator use or placebo and to evaluate the respiratory pattern
that would justify the development of dynamic
hyperinflation.
Methods
This was a prospective, randomized and double-blinded drug
study protocol. Sixteen consecutive COPD patients were
recruited from the pulmonary rehabilitation program at the
Sa˜o Paulo Federal University e Lar Escola Sa˜o Francisco,
Brazil. The study was approved by the Institution’s Ethics
Committee and the patients were enrolled in the protocol
once they had signed an informed consent form.
Inclusion criteria
Moderate to severe COPD patients according to the ATS/ERS
criteria (2004)7; stable clinical conditions without any
exacerbation within 30 days prior to the study; and patients
signed a consent form.Exclusion criteria
Associated comorbidities such as cardiac, orthopedic and
neurological diseases that would not allow normal function
of upper and lower limbs; inability to perform inspiratory
capacity maneuver; need for assisted oxygen use during the
incremental test due to peripheral arterial oxygen satura-
tion (SpO2) lower than 80%; lack of understanding of the
procedures; and current smoker or former smoker of less
than a year.
Protocol
All subjects had three laboratory visits. At the first visit
(visit 1) patients underwent a clinical assessment aiming to
assure their clinical stability and performed a vital capacity
pre- and post-bronchodilator test, both in the forced (FVC)
and slow (SVC) modalities.8
Patients returned for a second clinic visit (visit 2) at which
they received at random and double-blinded either inhaled
placebo or salbutamol (400 mcg). Salbutamol and placebo
canisters were identical except for a label referred to as A or
B. They rested for 45e60 min in order for the salbutamol to
achieve a pharmacodynamic steady state before starting the
exercise tests.19,20 Subsequently, a maximal incremental
upper limbs test using the second diagonal technique was
performed. Prior to and right after the exercise patients
performed a slow vital capacity in order to measure the
inspiratory capacity (IC) and the maximal inspiratory and
expiratory pressures (PImax and PEmax).
At the third visit, patients again performed a maximal
incremental exercise test with the upper limbs using the
second diagonal technique and according to the randomi-
zation on the second visit, they received the second drug
(inhaled placebo or salbutamol); IC, PImax and PEmax were
measured before and after the test.
Patients were allowed to use inhaled corticosteroids
during the trial. However, long-acting inhaled b2-agonists
were not allowed for at least 48 h before the screening visit
and throughout the study; short-acting anticholinergics or
b2-agonists were not allowed for at least 8 h before the
visits. Oral b2-agonists, antihistamines and theophylline
were not allowed for at least 1 month prior to the screening
visit. Tiotropium was not commercially available during the
study. Patients were allowed open-label salbutamol via
metered-dose inhaler as rescue medication when necessary.
Spirometry, muscle strength and upper limbs
exercise test assessment
Spirometry was done according to the criteria proposed by
the American Thoracic Society (ATS).9 PImax and PEmax
were measured with an aneroid manovacuometer. For both
tests the subject was in a seated position with a nose clip.
Table 1 Pulmonary function and anthropometric data of
16 COPD patients at baseline.
Pre-BD Post-BD p
Gender (M/F) 13/3 e e
Age (years) 63.1 13.5 e e
BMI (kg/m2) 25.9 6.0 e e
Pack/years history 31 12 e e
FVC (%) 69.4 14.4 74.0 13.0 0.0012
FVC (L) 2.95 0.7 3.26 0.8 0.004
FEV1 (%) 36.0 10.5 41.0 11.1 0.17
FEV1 (L) 1.35 0.6 1.50 0.7 0.096
FEV1/FVC 0.44 0.07 0.46 0.01 0.22
Mean standard deviation.
M/F: male/female.
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facilitation use is based on the fact that the execution of
movements in diagonal are considered to recruit a larger
number of muscle groups than other exercises. Diagonal
patterns accompanied by resistance are intended to elicit
irradiation and muscle recruitment. This diagonalespiral
pattern with a rotary component involves movements in
three dimensions with sequential and simultaneous move-
ments of several joints. The first diagonal technique includes
flexioneadductioneexternal rotation of the shoulders
motions, while the second diagonal technique includes
a flexioneabductioneexternal rotation motion.12,21 Others
have demonstrated the beneficial effect of the propriocep-
tive neuromuscular facilitation method in COPD patients
including an improvement in their arm functional capacity
and reduction in dyspnea and fatigue ratings.24,25
The exercise assessment was accomplished with an upper
limb’s maximal incremental exercise test performed with
both arms alternately using the second diagonal movement
of the proprioceptive neuromuscular facilitation. This diag-
onal movement is accomplished starting with the hand in the
contralateral side over the iliac crest, and then the arm is
lifted up with a flexion, abduction, and external rotation of
the shoulder following an arch of movement.
Subjects starting the test performing the movement
cited above holding a weight of 0.25 kilogram (kg) in each
hand and raised the arms alternately. Every 2 min the
weights were increased by 0.25 kg and a new set of repe-
titions were carried out without interruption. The test was
interrupted only when the patient was no longer able to
continue the exercise due to fatigue or compensation
movement using other muscle groups. The test was carried
out with the subjects in the standing position.
Before the test heart rate (HR), respiratory frequency
(f), SpO2, dyspnea and upper limbs fatigue were measured.
During the test breath-by-breath measurement of tidal
volume (VT), minute ventilation (VE), oxygen consumption
(VO2), carbon dioxide production (VCO2), pulmonary
ventilation/oxygen consumption ratio (VE/VO2), pulmonary
ventilation/carbon dioxide production ratio (VE/VCO2),
inspiratory and expiratory time, inspiratory time/respira-
tory total time ratio (TI/TTOT) and respiratory quotient (R)
were registered. Every 2 min HR, SpO2 and dyspnea sensa-
tion were measured.
To assess ventilatory and metabolic variables, patients
breathed through a face mask fixed by straps to the back of
the patient’s head; a sample of the breathed air was
continuously collected and analyzed by O2 and CO2 sensors
(K4b2 Cosmed, Italy).
Statistical analysis
The sample consisted of 16 subjects with aZ 0.05 and
a bZ 0.20 power being calculated according to the variability
of IC measurements according from various studies.11,18,19,22
Data are shown in mean, median and standard deviation.
Analysis of variance of repeated measures was used to
analyze similar repeated variables. Student’s t-test was used
to evaluate the same variable pre- and post-exercise.
When the variables did not follow a normal distribution the
ManneWhitney test was used to check the differences
between groups. To establish correlations, Pearson’scorrelation test was used. Moreover, odds ratio test was used
to assess variables whichmay lead to dynamic hyperinflation.
Statistical significance was determined by p< 0.05.
Results
Table 1 shows baseline anthropometric and pulmonary
function data of the 16 patients (81.5% male and 18.5%
female) included in the study, 100% were former smokers
with 31 12 pack/years, 25% were using inhaled cortico-
steroid and only 6% of subjects had been hospitalized in the
previous year.
Inspiratory capacity pre- and post-bronchodilator
Values found for IC at rest after placebo and after bron-
chodilator were 2.32 0.44 (2.09e2.56 L) and 2.54 0.39 L
(2.33e2.76 L), respectively, (pZ 0.0012); 62.5% of the
group presented IC enhancement in at least 150 mL and/or
10% after bronchodilator use (Fig. 1).
Upper limb exercise test with placebo
Reduction of 222 158 ml or 9.8% in the IC after upper limb
exercises with placebo was observed (p< 0.0001); 62.5% of
the patients hyperinflated and 60% of them presented both
a reduction of IC above 10% plus a loss greater than 150 mL.
Mean baseline IC was 2.35 0.44 L (2.11e2.59 L) and the
median was 2.34 L (Fig. 2).
Upper limb exercise test after the use of
a bronchodilator
No significant reduction in the IC after upper limb exercise
test with the use of bronchodilator (salbutamol 400 mcg)
was found. The difference of IC between baseline and end
of the exercise test was 103.8 205.0 mL, or 4.4%, with
a median value of 105.0 mL (pZ 0.41); only 25% of subjects
presented a loss of IC greater than 150 mL whereas 12.5%
patients had a loss greater than 10%. Overall, 12.3% of the
patients presented an IC increase after the exercise test
(Fig. 3).
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Figure 1 Inspiratory capacity at rest before and after the use
of 400 mcg of salbutamol (2.32 and 2.54 mean values) in 16
moderate to severe COPD patients (p< 0.0012).
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Figure 3 Inspiratory capacity before and after an upper
limbs incremental exercise test with the previous use of
400 mcg of salbutamol (2.44 L and 2.32 L mean values) in 16
moderate to severe COPD patients (NSZ non significant).
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hyperinflate after upper limb exercise test
Sixty-two percent of subjects who hyperinflated at the end
of the exercise test presented lower baseline values of
FEV1/FVC (pZ 0.0067), FEV1% predicted (pZ 0.0091), IC%
predicted (pZ 0.043), higher values of VO2 mL/min %max-
imal predicted (pZ 0.05), respiratory frequency (pZ
0.023) and pulmonary ventilation (pZ 0.009). Age, BMI,
FVC, SpO2, difference between pre- and post- (delta) PImax
and PEmax values, VO2(L), VE/VO2, VE/VCO2, upper limbs
maximal load and Borg for dyspnea sensation were not
statistically different (p> 0.05) (Table 2).
Ventilatory pattern with bronchodilator and with
placebo in upper limbs exercise test
The exercise performed after the use of placebo showed
a higher minuteeventilation (pZ 0.0021), respiratory
frequency (pZ 0.002), VE/MVV ratio (pZ 0.031) and VT/TI
(p< 0.05), and a shorter expiratory time at peak exerciseBefore-exercise After-exercise
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Figure 2 Inspiratory capacity before and after an incre-
mental upper limbs exercise test without bronchodilator
(2.34 L and 2.12 L mean values) in 16 moderate to severe COPD
patients (p< 0.05).than the exercise performed with the use of a bronchodi-
lator (pZ 0.015) (Table 3).
Correlation between pre- and post- (delta)
pulmonary ventilation and IC values after upper
limbs exercise test
A significant and positive correlation between the difference
between pre- and post- (delta) pulmonary ventilation and
pre- and post- (delta) IC values with upper limbs exercise test
with placebo was found [rZ 0.82 (p< 0.0001)] (Fig. 4).
Dyspnea sensation
Dyspnea sensation after upper limbs exercise test assessed
by using Borg scale was 3.81 (1.0e8.0) and 2.31 (0e5.0)
after placebo and after the use of bronchodilator, respec-
tively, (pZ 0.06) (Fig. 5). At the end of the upper limbs test
using a bronchodilator, 87% of subjects presented less
dyspnea sensation than when the test was accomplished
with the use of placebo and 13% of subjects kept the same
dyspnea sensation in both situations. The use of placebo
prior to the exercise increases the risk of developing
hyperinflation (OR: 5.0, IC 95%: 1.23e13.3).
Discussion
We believe our study has three important findings: first,
upper limbs exercise may cause significant hyperinflation;
secondly, the use of a bronchodilator significantly enhanced
the inspiratory capacity; thirdly, the use of salbutamol prior
to exercise prevented hyperinflation development.
Inspiratory capacity decrease during physical activity
reflects dynamic pulmonary hyperinflation, and is easy to
be measured, is inexpensive, is non-invasive and has
already been demonstrated to be a reproducible and reli-
able maneuver.10
In this study upper limbs exercise was accomplished per-
forming the second diagonal exercise of the proprioceptive
neuromuscular facilitation technique as it is more functional
Table 2 Data of the COPD patients who presented hyperinflation (loss greater than 150 mL and/or 10% of IC) and those who
did not hyperinflate during upper limb exercises.
Variables Hyperinflated Non-hyperinflated p
N (%) (62) 38
Age (years) 62.2(5.3) 59.5(4.1) 0.26
BMI (kg/m2) 23.9(2.4) 28.8(4.1) 0.30
FVC (%) 71.9(16) 65.3(13.4) 0.25
FEV1/FVC 0.40 50.8 0.0067
FEV1 (%) 34.7(5) 45.5(7) 0.0091
IC (% predicted) 80.8(5.4) 96.0(13.2) 0.043
VO2/ml/kg/min
(%max predicted)
59.0(16) 46.0(13) 0.05
Respiratory frequency 30.0(6) 24.0(5) 0.023
VE (L) 31.3(7.4) 28.7(6.3) 0.009
SpO2 (%) 91.3(7.4) 94.3(5) 0.25
DPImax. Pre- and post-upper
limbs exercise (cmH2O)
3.5 6.0 0.57
DPEmax. Pre- and post-upper
limbs exercise (cmH2O)
2.5 4.1 0.51
DBorg 3.4 2.5 0.58
VE/VO2 (L) 41.3 39.4 0.58
VE/VCO2 (L) 44.3 45.3 0.42
Upper limbs maximal load (kg) 1.9 1.6 0.13
Mean (standard deviation).
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larger number of muscle recruitment and activities of daily
living simulation.12
Proprioceptive and kinesthetic deficits are known to occur
after certain types of injuries, and the use of proprioceptive
neuromuscular facilitation techniques to correct these
problems is considered more efficacious than the traditional
static stretching exercises. The basis of this therapeutic
system is predicated on the involvement of four neurophysi-
ological mechanisms: reflexes, resistance, irradiation, and
successive induction. Irradiation is the ‘‘spread of excitation
in the central nervous system which causes contraction of
synergistic muscles in a specific pattern.’’ Successive induc-
tion refers to contraction of an agonist muscle group followedTable 3 Ventilatory pattern at rest and at the peak of
upper limbs exercises test.
Upper limbs exercise test
With placebo With bronchodilator
Rest Peak Rest Peak
VE (L) 14.1 31.0** 14.2 23.5
VD/VT 0.40 0.50 0.30 0.30
RR (bpm) 21.0 26.0** 21.0 22.0
TI (s) 1.10 0.90 1.10 1.0
TE (s) 1.00 1.40* 2.00 1.9
TI/TTOT 0.40 0.40 0.40 0.48
VT/TI (L/s) 0.63 1.10* 0.63 0.90
VT (L) 0.70 1.00 0.70 0.90
VE/MVV 0.23 0.53* 0.24 0.41
**p< 0.005, *p< 0.05 peak exercise test without vs with
bronchodilator.by activation of the antagonist muscle group.12,21 Also,
several studies showed beneficial training effect in COPD
patients with this type of exercise.24,25
Few studies have evaluated the ventilatory response
during upper limb activities. Celli et al showed that the
simple arm elevation by a COPD patient leads to a decrease
in tidal volume, a 16% increase in oxygen consumption and
a 24% increase in pulmonary ventilation. They also showed
that there is an increase in the gastric (Pg) and trans-
diaphragmatic pressures (Pdi) suggesting that arm elevation
alters muscle activation and changes the chest wall
mechanics.13,14 Velloso et al showed that COPD patients
have a high rest pulmonary ventilation which could be
further enhanced when performing simple upper limbs
activities of daily living.150
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Figure 4 Correlation between increase in pulmonary venti-
lation and decrease in the inspiratory capacity after upper
limbs exercise test without bronchodilator.
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Figure 5 DBorg (pre-post) with bronchodilator and with
placebo after upper limbs exercise.
Supplementary information
Supplementary data associated with this article can be
found in the online version, at doi:10.1016/j.rmed.
2008.08.018.
256 E.F. Porto et al.The use of a bronchodilator has been reported as
a conventional method in order to diminish the respiratory
system workload. O’Donnell et al have described that the
COPD patients’ performance during lower limb exercises
using tiotropium might assure less ventilatory stress and
less pulmonary hyperinflation.16 In our study pulmonary
ventilation during upper limb exercises with placebo use
was significantly greater than during the same exercise
using salbutamol (31 versus 23.5 liters, respectively). This
means that when patients inhaled the bronchodilator, lung
deflation occurred leading to a lower end expiratory lung
volume (EELV) and, consequently, generating a greater
ventilatory reserve (VVM-VEmax). At this new lung volume
less mechanical load was imposed on the respiratory
muscles and a greater respiratory endurance was achieved.
Another important finding in our study was that the use of
bronchodilator not only decreased the static hyperinflation
but also prevented dynamic hyperinflation to occur during
exercise despite the fact that it did not increase airflow.
Traditionally, FEV1 has been used to measure the broncho-
dilator response in COPD patients, however, some patients
respond predominantly by increasing their lung volume after
the use of bronchodilator.6,17 Studies have shown that the
reduction of dyspnea sensation that follows a decrease in
hyperinflation may be more important than the FEV1
improvement.16,18 In the present study, a significant
enhancement of FVC and IC was found after the use of
a bronchodilator, with dyspnea sensation reduction, without
FEV1 improvement. This benefit suggests that the use of
a bronchodilator should be a recommendation previous to
any physical activity in COPD patients, including those
accomplished by upper limbs. We found that placebo use
alone prior to exercise increases hyperinflation-developing
risk (OR: 5.0, IC 95%: 1.23e13.3). Celli et al6 and O’Donnell
et al16 showed that a long-acting anticholinergic drug (tio-
tropium) reduces static and dynamic hyperinflation,
respectively, enhancing physical capacity in COPD patients.
Aliverti et al had already shown that salbutamol use
reduces dynamic hyperinflation in COPD patients during
lower limbs incremental leg tests, increasing endurance as
well as the final workload.19 Others found the same effect
with the use of salmeterol.20,22,23As far as we know there is no study in the literature that
has evaluated dynamic hyperinflation reduction with
bronchodilator use in COPD patients performing upper limb
exercises. So, this is the first study to show the modulation
of operational lung volumes during the accomplishment of
upper limb exercises in COPD patients after salbutamol
inhalation.
Sixty percent of our patients hyperinflated. We found
additional factors that are associated with dynamic
hyperinflation: lower baseline values of airflow obstruction
(FEV1), FEV1/FVC ratio, inspiratory capacity in percent of
predicted and higher baseline values of VO2 ml/kg/min %-
predicted, respiratory frequency and pulmonary ventilation
at the same metabolic stress. This means that a COPD
patient will be more prone to hyperinflate after performing
upper limb exercises or activities whenever severe
obstruction, high respiratory drive and less metabolic and
ventilatory reserve are associated.
In summary, the use of a b-agonist bronchodilator
reduces static hyperinflation and prevents dynamic hyper-
inflation occurrence during upper limb exercises. These
findings point out that the use of bronchodilator medica-
tions in COPD patients previous to physical exercises is
beneficial. Patients at greater risk of hyperinflation devel-
opment during upper limb exercises are those with severe
airflow obstruction and with a reduced inspiratory capacity.
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